drugset
drugset / Trial / NCT05851027

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

NCT05851027 ↗

Phase 2/3 Completed 50 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of QL0911 in Chemotherapy- Induced Thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of chemotherapy.

Timeline

Start
2021-01-15
Primary completion
2021-09-10
Completion
2021-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject QL0911 Protein / enzyme biologic 1 ug/kg Subcutaneous
Subject QL0911 Protein / enzyme biologic 2 ug/kg Subcutaneous

Indications

thrombocytopenia